Financial

Over time, the graveyard of failed orthopedic companies that has become more crowded. People don’t like to talk about the […]

An ortho friend asked me this interesting financial question and there is a simple answer. This is a classic case

Following up to the original article – Globus continues to eat orthopedics with fantastic financial numbers including 25% revenue growth

This announced partnership confuses me – Smith+Nephew signs distribution agreement with SI-BONE. I am still trying to wrap my head

Why Read? Let me be crystal clear. The purpose of this article is to “right a clinical wrong”.We must: 1/

I am a small company guy, but cannot ignore the Big Orthos as part of my job, so sharing an

JPM 2026: From “Recovery” to “Execution” The “growth at all costs” era is officially dead. The vibe at the 44th

Immediate R&D Tax Breaks are Back A major change in tax law (the “One Big Beautiful Bill Act”) is a

A small dose of greed can be a good thing for orthopedic company leaders… but excessive greed can be problematic.

Arthrex, the Naples-based giant known for its sports med dominance, is making a bold leap into total joints by acquiring

In orthopedic M&A, one audacious open letter stands as a masterclass in disruption. Back in 2003, Smith & Nephew had

Tiger’s Take This acquisition may trigger more fundings and more M&A in the Sports Med space. About a year ago,

In our ortho industry, we spend an incredible amount of time obsessing over implant geometry, surface coatings, and robotic precision.

Market conditions in Ortho are tighter than a locked pedicle screw these days—extended sales processes, rising costs, regulatory hurdles, and

The Medline IPO is a strong signal. Maybe we will see more Ortho PE IPOs in 2026. I would watch

If you are not an OrthoStreams subscriber, you can read the full details here – https://lnkd.in/g7dS_B4K Tiger Buford and Andrea Davis are brokering

As we prepare to enter 2026, Surgeons are still being blasted with features, features, features at medical shows and over

If you’ve been in the ortho industry for any time, you know the big dogs like Stryker, Zimmer Biomet, and

Heard on the street. This is going to be a wild few months with a ton of disruption in people.

Why Read? This article explores a proven “ASC-only” strategy via an 8-step playbook for entrepreneurs, covering ASC-optimized product design, partnerships,

It’s earnings season and we had two crazy stock moves after Q3 2025 earnings calls last week. Globus accelerated and

In the world of orthopedics, few stories capture the highs and lows like Exactech’s— from groundbreaking innovation to crippling recalls

Tiger’s Take: Acumed has made a strategic purchase of certain assets developed by TECHFIT Digital Surgery, particularly the DISRP online

The current funding environment is notoriously challenging, particularly in the Ortho space. On a discussion with the BoneChat community, finance

The Big Orthos continue to grow with their access advantages, new products from M&A, and organized sales force. The pattern

I received a call from an orthopedic surgeon: “How do I break into venture capital as a physician?” The answer

Venture money has been tight for over three years and counting, so a few ortho businesses are tapping into the

Tiger’s 5 quick takes: 1/ Ortho Access Wars This move validates my point that innovating in Ortho has gotten harder

Why Read? As a leader of a nimble ortho company navigating tight margins and fierce competition, this article arms you

I recently covered Carlsmed’s bold $100M IPO bid, noting how rare orthopedic offerings have been in recent years. Now, Shoulder

Disclaimer: This is not legal advice or financial advice and I do not own any Treace stock. OK, not let’s

This acquisition story is complicated and changing day-to-day. Let me try to make sense of this saga. Websites – https://integrum.se/

Why Read? Read this if you want to understand hospital value analysis demystifies procurement barriers for small orthopedics device companies.

In an era where venture capital flows like molasses—particularly for fledgling spine startups navigating regulatory hurdles, market saturation, and investor

This article is worth reading because it uncovers the harsh realities and cautionary tales behind failed orthopedic startups, offering invaluable

This concerning trend is gaining momentum: major hospital networks are increasingly resistant to adopting innovative orthopedic devices. Metaphorically speaking, these

This is a sign of the times. In the spine sector, a stark imbalance persists: the pool of spine surgeons

This article dissects Montagu Private Equity’s ambitious rollup of three orthopedic device companies, comparing it to their proven Nemera playbook,

Quick Summary restor3d’s $104 million investment from Partners Group, including $65 million in new equity, offers significant advantages: it accelerates

By exploring the intellectual property feud between Globus Medical and Life Spine, you will uncover the intricacies of a high-stakes

For orthopedic companies seeking funding to innovate, grow, or scale, understanding the landscape of potential investors is crucial. Based on

I’m scratching my head here. ZB, the world’s leader in total joint implant sales, just dropped $177M (before earnouts) to

Disclaimer: This is not financial advice, and investors should conduct their own due diligence before making any investment decisions. Tiger’s